- Home
- VALN
VALN
Valneva SE
as 07-26-2024 4:00pm EST
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.
| Founded: | 2012 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 494.0M | IPO Year: | 2021 |
| Target Price: | $21.50 | AVG Volume (30 days): | 6.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.58 - $15.28 | Next Earning Date: | 09-19-2024 |
| Revenue: | $166,258,696 | Revenue Growth: | -58.99% |
| Revenue Growth (this year): | 37.72% | Revenue Growth (next year): | 5.63% |
Latest Valneva SE News
VALN Breaking Stock News: Dive into VALN Ticker-Specific Updates for Smart Investing
Zacks
11 hours ago
Can Valneva (VALN) Climb 149.04% to Reach the Level Wall Street Analysts Expect?
Clinical Trials Arena
5 days ago
Valneva and CEPI expand deal for chikungunya vaccine trials
GlobeNewswire
5 days ago
CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine
Benzinga
8 days ago
Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
GlobeNewswire
9 days ago
Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion
Zacks
18 days ago
Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine
GlobeNewswire
22 days ago
Declaration of shares and voting rights - Valneva SE - June 30, 2024
MT Newswires
25 days ago
Valneva's Secures Marketing Authorization in Europe for Chikungunya Vaccine
Compare VALN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VALN Valneva SE - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.